TocilizumabV1, France, Analysis, bibRecord, 000265

Investigational drugs in recent clinical trials for treatment-resistant depression

Identifieur interne : 000265 ( France/Analysis ); précédent : 000264; suivant : 000266

Investigational drugs in recent clinical trials for treatment-resistant depression

Auteurs : Ricardo P. Garay [France] ; Carlos A. Zarate [États-Unis] ; Thomas Charpeaud [France] ; Leslie Citrome [États-Unis] ; Christoph U. Correll [États-Unis] ; Ahcène Hameg [France] ; Pierre-Michel Llorca [France]

Source :

Expert review of neurotherapeutics [ 1473-7175 ] ; 2017.

RBID : PMC:5418088

Abstract

Introduction

The authors describe the medications for treatment-resistant depression (TRD) in phase II/III of clinical development in the EU and USA and provide an opinion on how current treatment can be improved in the near future.

Areas covered

Sixty-two trials were identified in US and EU clinical trial registries that included six investigational compounds in recent phase III development and 12 others in recent phase II clinical trials. Glutamatergic agents have been the focus of many studies. A single intravenous dose of the glutamatergic modulator ketamine produces a robust and rapid antidepressant effect in persons with TRD; this effect continues to remain significant for 1 week. This observation was a turning point that opened the way for other, more selective glutamatergic modulators (intranasal esketamine, AVP-786, AVP-923, AV-101, and rapastinel). Of the remaining compounds, monoclonal antibodies open highly innovative therapeutic options, based on new pathophysiological approaches to depression.

Expert commentary

Promising new agents are emerging for TRD treatment. Glutamatergic modulators likely represent a very promising alternative to monoaminergic antidepressant monotherapy. We could see the arrival of the first robust and rapid acting antidepressant drug in the near future, which would strongly facilitate the ultimate goal of recovery in persons with TRD.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418088

DOI: 10.1080/14737175.2017.1283217
PubMed: 28092469
PubMed Central: 5418088

Affiliations:

Links to Exploration step

PMC:5418088

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Investigational drugs in recent clinical trials for treatment-resistant depression</title>
<author><name sortKey="Garay, Ricardo P" sort="Garay, Ricardo P" uniqKey="Garay R" first="Ricardo P." last="Garay">Ricardo P. Garay</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Pharmacology and Therapeutics, Craven, Villemoisson-sur-Orge, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Pharmacology and Therapeutics, Craven, Villemoisson-sur-Orge</wicri:regionArea>
<wicri:noRegion>Villemoisson-sur-Orge</wicri:noRegion>
<wicri:noRegion>Villemoisson-sur-Orge</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zarate, Carlos A" sort="Zarate, Carlos A" uniqKey="Zarate C" first="Carlos A." last="Zarate">Carlos A. Zarate</name>
<affiliation wicri:level="2"><nlm:aff id="A2">Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Charpeaud, Thomas" sort="Charpeaud, Thomas" uniqKey="Charpeaud T" first="Thomas" last="Charpeaud">Thomas Charpeaud</name>
<affiliation wicri:level="3"><nlm:aff id="A3">Centre Médico-Psychologique B, CHU, Université d’Auvergne, Clermont-Ferrand, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre Médico-Psychologique B, CHU, Université d’Auvergne, Clermont-Ferrand</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Auvergne (région administrative)</region>
<settlement type="city">Clermont-Ferrand</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Citrome, Leslie" sort="Citrome, Leslie" uniqKey="Citrome L" first="Leslie" last="Citrome">Leslie Citrome</name>
<affiliation wicri:level="2"><nlm:aff id="A4">Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Correll, Christoph U" sort="Correll, Christoph U" uniqKey="Correll C" first="Christoph U." last="Correll">Christoph U. Correll</name>
<affiliation wicri:level="2"><nlm:aff id="A5">Psychiatry Research, Northwell Health, The Zucker Hillside Hospital, Glen Oaks, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Psychiatry Research, Northwell Health, The Zucker Hillside Hospital, Glen Oaks, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A6">Hofstra Northwell Health School of Medicine, Hempstead, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Hofstra Northwell Health School of Medicine, Hempstead, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hameg, Ahcene" sort="Hameg, Ahcene" uniqKey="Hameg A" first="Ahcène" last="Hameg">Ahcène Hameg</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Pharmacology and Therapeutics, Craven, Villemoisson-sur-Orge, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Pharmacology and Therapeutics, Craven, Villemoisson-sur-Orge</wicri:regionArea>
<wicri:noRegion>Villemoisson-sur-Orge</wicri:noRegion>
<wicri:noRegion>Villemoisson-sur-Orge</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Llorca, Pierre Michel" sort="Llorca, Pierre Michel" uniqKey="Llorca P" first="Pierre-Michel" last="Llorca">Pierre-Michel Llorca</name>
<affiliation wicri:level="3"><nlm:aff id="A3">Centre Médico-Psychologique B, CHU, Université d’Auvergne, Clermont-Ferrand, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre Médico-Psychologique B, CHU, Université d’Auvergne, Clermont-Ferrand</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Auvergne (région administrative)</region>
<settlement type="city">Clermont-Ferrand</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">28092469</idno>
<idno type="pmc">5418088</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418088</idno>
<idno type="RBID">PMC:5418088</idno>
<idno type="doi">10.1080/14737175.2017.1283217</idno>
<date when="2017">2017</date>
<idno type="wicri:Area/Pmc/Corpus">000827</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000827</idno>
<idno type="wicri:Area/Pmc/Curation">000827</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000827</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000D93</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000D93</idno>
<idno type="wicri:Area/Ncbi/Merge">001456</idno>
<idno type="wicri:Area/Ncbi/Curation">001456</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001456</idno>
<idno type="wicri:doubleKey">1473-7175:2017:Garay R:investigational:drugs:in</idno>
<idno type="wicri:Area/Main/Merge">001768</idno>
<idno type="wicri:Area/Main/Curation">001769</idno>
<idno type="wicri:Area/Main/Exploration">001769</idno>
<idno type="wicri:Area/France/Extraction">000265</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Investigational drugs in recent clinical trials for treatment-resistant depression</title>
<author><name sortKey="Garay, Ricardo P" sort="Garay, Ricardo P" uniqKey="Garay R" first="Ricardo P." last="Garay">Ricardo P. Garay</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Pharmacology and Therapeutics, Craven, Villemoisson-sur-Orge, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Pharmacology and Therapeutics, Craven, Villemoisson-sur-Orge</wicri:regionArea>
<wicri:noRegion>Villemoisson-sur-Orge</wicri:noRegion>
<wicri:noRegion>Villemoisson-sur-Orge</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zarate, Carlos A" sort="Zarate, Carlos A" uniqKey="Zarate C" first="Carlos A." last="Zarate">Carlos A. Zarate</name>
<affiliation wicri:level="2"><nlm:aff id="A2">Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Charpeaud, Thomas" sort="Charpeaud, Thomas" uniqKey="Charpeaud T" first="Thomas" last="Charpeaud">Thomas Charpeaud</name>
<affiliation wicri:level="3"><nlm:aff id="A3">Centre Médico-Psychologique B, CHU, Université d’Auvergne, Clermont-Ferrand, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre Médico-Psychologique B, CHU, Université d’Auvergne, Clermont-Ferrand</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Auvergne (région administrative)</region>
<settlement type="city">Clermont-Ferrand</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Citrome, Leslie" sort="Citrome, Leslie" uniqKey="Citrome L" first="Leslie" last="Citrome">Leslie Citrome</name>
<affiliation wicri:level="2"><nlm:aff id="A4">Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Correll, Christoph U" sort="Correll, Christoph U" uniqKey="Correll C" first="Christoph U." last="Correll">Christoph U. Correll</name>
<affiliation wicri:level="2"><nlm:aff id="A5">Psychiatry Research, Northwell Health, The Zucker Hillside Hospital, Glen Oaks, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Psychiatry Research, Northwell Health, The Zucker Hillside Hospital, Glen Oaks, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A6">Hofstra Northwell Health School of Medicine, Hempstead, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Hofstra Northwell Health School of Medicine, Hempstead, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hameg, Ahcene" sort="Hameg, Ahcene" uniqKey="Hameg A" first="Ahcène" last="Hameg">Ahcène Hameg</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Pharmacology and Therapeutics, Craven, Villemoisson-sur-Orge, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Pharmacology and Therapeutics, Craven, Villemoisson-sur-Orge</wicri:regionArea>
<wicri:noRegion>Villemoisson-sur-Orge</wicri:noRegion>
<wicri:noRegion>Villemoisson-sur-Orge</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Llorca, Pierre Michel" sort="Llorca, Pierre Michel" uniqKey="Llorca P" first="Pierre-Michel" last="Llorca">Pierre-Michel Llorca</name>
<affiliation wicri:level="3"><nlm:aff id="A3">Centre Médico-Psychologique B, CHU, Université d’Auvergne, Clermont-Ferrand, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre Médico-Psychologique B, CHU, Université d’Auvergne, Clermont-Ferrand</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Auvergne (région administrative)</region>
<settlement type="city">Clermont-Ferrand</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Expert review of neurotherapeutics</title>
<idno type="ISSN">1473-7175</idno>
<idno type="eISSN">1744-8360</idno>
<imprint><date when="2017">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="S1"><title>Introduction</title>
<p id="P1">The authors describe the medications for treatment-resistant depression (TRD) in phase II/III of clinical development in the EU and USA and provide an opinion on how current treatment can be improved in the near future.</p>
</sec>
<sec id="S2"><title>Areas covered</title>
<p id="P2">Sixty-two trials were identified in US and EU clinical trial registries that included six investigational compounds in recent phase III development and 12 others in recent phase II clinical trials. Glutamatergic agents have been the focus of many studies. A single intravenous dose of the glutamatergic modulator ketamine produces a robust and rapid antidepressant effect in persons with TRD; this effect continues to remain significant for 1 week. This observation was a turning point that opened the way for other, more selective glutamatergic modulators (intranasal esketamine, AVP-786, AVP-923, AV-101, and rapastinel). Of the remaining compounds, monoclonal antibodies open highly innovative therapeutic options, based on new pathophysiological approaches to depression.</p>
</sec>
<sec id="S3"><title>Expert commentary</title>
<p id="P3">Promising new agents are emerging for TRD treatment. Glutamatergic modulators likely represent a very promising alternative to monoaminergic antidepressant monotherapy. We could see the arrival of the first robust and rapid acting antidepressant drug in the near future, which would strongly facilitate the ultimate goal of recovery in persons with TRD.</p>
</sec>
</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
<li>États-Unis</li>
</country>
<region><li>Auvergne (région administrative)</li>
<li>Auvergne-Rhône-Alpes</li>
<li>Maryland</li>
<li>État de New York</li>
</region>
<settlement><li>Clermont-Ferrand</li>
</settlement>
</list>
<tree><country name="France"><noRegion><name sortKey="Garay, Ricardo P" sort="Garay, Ricardo P" uniqKey="Garay R" first="Ricardo P." last="Garay">Ricardo P. Garay</name>
</noRegion>
<name sortKey="Charpeaud, Thomas" sort="Charpeaud, Thomas" uniqKey="Charpeaud T" first="Thomas" last="Charpeaud">Thomas Charpeaud</name>
<name sortKey="Hameg, Ahcene" sort="Hameg, Ahcene" uniqKey="Hameg A" first="Ahcène" last="Hameg">Ahcène Hameg</name>
<name sortKey="Llorca, Pierre Michel" sort="Llorca, Pierre Michel" uniqKey="Llorca P" first="Pierre-Michel" last="Llorca">Pierre-Michel Llorca</name>
</country>
<country name="États-Unis"><region name="Maryland"><name sortKey="Zarate, Carlos A" sort="Zarate, Carlos A" uniqKey="Zarate C" first="Carlos A." last="Zarate">Carlos A. Zarate</name>
</region>
<name sortKey="Citrome, Leslie" sort="Citrome, Leslie" uniqKey="Citrome L" first="Leslie" last="Citrome">Leslie Citrome</name>
<name sortKey="Correll, Christoph U" sort="Correll, Christoph U" uniqKey="Correll C" first="Christoph U." last="Correll">Christoph U. Correll</name>
<name sortKey="Correll, Christoph U" sort="Correll, Christoph U" uniqKey="Correll C" first="Christoph U." last="Correll">Christoph U. Correll</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000265 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000265 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     PMC:5418088
   |texte=   Investigational drugs in recent clinical trials for treatment-resistant depression
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/RBID.i   -Sk "pubmed:28092469" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd   \
       | NlmPubMed2Wicri -a TocilizumabV1

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021

Serveur d'exploration Tocilizumab

Investigational drugs in recent clinical trials for treatment-resistant depression

Investigational drugs in recent clinical trials for treatment-resistant depression

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration Tocilizumab
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.